Pseudomonas Aeruginosa - Inhalation treatment, biomarkers and quality of life - Pseudomonas, Tazocin or Colistin

Aarhus University Hospital, Department of Respiratory Medicine0 个研究点开始时间: 2015年9月22日最近更新: 2017年10月2日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in this study, the patient must meet all of the following criteria:
•·Signed informed consent to participate in the study in accordance with local
•regulations
•·Diagnosed with a chronic pulmonary disease by lung functions test or CT
•·Diagnosed with one positive sputum sample with PA during the last year
•·Age 18 - 85 years inclusive
•·Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study
•procedures specified in the protocol.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 70

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•·Prophylactic treatment with any other antibiotic
•·Allergy to tazocin, ciprofloxacin or colistimethate-sodium
•·Patients who are pregnant or planning a pregnancy
•·Patients with any solid organ transplant
•·Patients with cystic fibrosis
•·Patients on assisted ventilation
•·Bronchiectasis as a consequence of cystic fibrosis or focal endobronchial
•lesion or otherwise curable causes (e.g. foreign body aspiration)
•·Be considered terminally ill or listed for transplantation
•·Actively treated Mycobacterium tuberculosis or other mycobacteria
•·Patients in a condition or in a situation, which in the investigator's opinion
•may put the subject at significant risk, may confound results or may interfere
•significantly with the patient's participation in the study

发起方

Aarhus University Hospital, Department of Respiratory Medicine